Search results for "GPI-Linked Protein"

showing 10 items of 19 documents

Sox17 regulates liver lipid metabolism and adaptation to fasting.

2014

Liver is a major regulator of lipid metabolism and adaptation to fasting, a process involving PPARalpha activation. We recently showed that the Vnn1 gene is a PPARalpha target gene in liver and that release of the Vanin-1 pantetheinase in serum is a biomarker of PPARalpha activation. Here we set up a screen to identify new regulators of adaptation to fasting using the serum Vanin-1 as a marker of PPARalpha activation. Mutagenized mice were screened for low serum Vanin-1 expression. Functional interactions with PPARalpha were investigated by combining transcriptomic, biochemical and metabolic approaches. We characterized a new mutant mouse in which hepatic and serum expression of Vanin-1 is …

medicine.medical_specialtyTransgeneMutantPeroxisome proliferator-activated receptorlcsh:MedicineMice TransgenicGastroenterology and HepatologyBiologyGPI-Linked ProteinsAmidohydrolasesMiceInternal medicineHMGB ProteinsMolecular Cell BiologymedicineMedicine and Health SciencesSOXF Transcription FactorsAnimalsPPAR alphalcsh:ScienceBeta oxidationchemistry.chemical_classificationMultidisciplinaryFatty liverlcsh:RBiology and Life SciencesLipid metabolismSOX9 Transcription FactorCell BiologyFastingmedicine.diseaseLipid MetabolismAdaptation Physiological3. Good healthEndocrinologychemistryPantetheinaseLiverlipids (amino acids peptides and proteins)lcsh:QTranscriptomeDrug metabolismResearch ArticlePLoS ONE
researchProduct

Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children

2016

PURPOSE: The effect of growth hormone (GH) on adipose tissue and the role of adipokines in modulating metabolism are documented, but with discordant data. Our aim was to evaluate the impact of GH treatment on a series of selected adipokines known to have a metabolic role and poorly investigated in this setting. METHODS: This is a prospective study. Thirty-one prepubertal children (25 M, 6 F; aged 8.5 ± 1.6 years) with isolated GH deficiency treated with GH for at least 12 months and 30 matched controls were evaluated. Auxological and metabolic parameters, insulin sensitivity indexes, leptin, soluble leptin receptor, adiponectin, visfatin, resistin, omentin, adipocyte fatty acid-binding prot…

0301 basic medicineLeptinMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipokineAdipose tissue030209 endocrinology & metabolismEnzyme-Linked Immunosorbent AssayGPI-Linked ProteinsAdipokines; Children; Growth hormone; Insulin sensitivitySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineAdipocyteLectinsAdipokinemedicineHumansResistinProspective StudiesChildNicotinamide PhosphoribosyltransferaseChildrenGrowth hormoneGrowth DisordersLeptin receptorAdiponectinbusiness.industryHuman Growth HormoneLeptinInsulinInsulin sensitivityHormones030104 developmental biologyEndocrinologychemistryCase-Control StudiesChild PreschoolCytokinesResistinFemalebusinessBiomarkers
researchProduct

Stromal hyaluronan accumulation is associated with low immune response and poor prognosis in pancreatic cancer

2021

AbstractHyaluronan (HA) accumulation has been associated with poor survival in various cancers, but the mechanisms for this phenomenon are still unclear. The aim of this study was to investigate the prognostic significance of stromal HA accumulation and its association with host immune response in pancreatic ductal adenocarcinoma (PDAC). The study material consisted of 101 radically treated patients for PDAC from a single geographical area. HA staining was evaluated using a HA-specific probe, and the patterns of CD3, CD8, CD73 and PD-L1 expression were evaluated using immunohistochemistry. HA staining intensity of tumour stromal areas was assessed digitally using QuPath. CD3- and CD8-based …

0301 basic medicineMalehyaluronaanibiomarkkeritB7-H1 Antigen0302 clinical medicineProspective StudiesHyaluronic Acid5'-NucleotidasehaimasyöpäCancerAged 80 and overMultidisciplinaryQGastroenterologyRMiddle AgedPrognosisSurvival RateOncology030220 oncology & carcinogenesisimmuunivasteImmunohistochemistryMedicineFemalesyöpätauditCarcinoma Pancreatic DuctalStromal cellScienceImmunologyGPI-Linked Proteins3121 Internal medicineArticle03 medical and health sciencesImmune systemPancreatic cancerCarcinomamedicineHumansSurvival rateAgedbusiness.industryImmunityCancerennusteetmedicine.disease3126 Surgery anesthesiology intensive care radiologyPancreatic Neoplasms030104 developmental biologyCancer researchStromal CellsbusinessCD8Follow-Up Studies
researchProduct

Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level

2011

International audience; TNF-related apoptosis-inducing ligand or Apo2L (Apo2L/TRAIL) is a promising anti-cancer drug owing to its ability to trigger apoptosis by binding to TRAIL-R1 or TRAIL-R2, two membrane-bound receptors that are often expressed by tumor cells. TRAIL can also bind non-functional receptors such as TRAIL-R4, but controversies still exist regarding their potential to inhibit TRAIL-induced apoptosis. We show here that TRAIL-R4, expressed either endogenously or ectopically, inhibits TRAIL-induced apoptosis. Interestingly, the combination of chemotherapeutic drugs with TRAIL restores tumor cell sensitivity to apoptosis in TRAIL-R4-expressing cells. This sensitization, which ma…

MESH: CASP8 and FADD-Like Apoptosis Regulating ProteinMESH : Antineoplastic Combined Chemotherapy ProtocolsCASP8 and FADD-Like Apoptosis Regulating ProteinTRAILApoptosisMESH : Models BiologicalMitochondrionMESH : RNA Small InterferingMESH: Caspase 8TNF-Related Apoptosis-Inducing LigandMESH : TNF-Related Apoptosis-Inducing LigandMESH : Tumor Necrosis Factor Decoy Receptors0302 clinical medicineRNA interferenceNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMESH: RNA Small InterferingMESH: NeoplasmsRNA Small InterferingReceptorSensitizationCaspase 80303 health sciencesMESH : Caspase 8MESH: Drug Resistance Neoplasm3. Good healthCell biologyMESH: Antineoplastic Combined Chemotherapy ProtocolsMESH : Drug Resistance Neoplasmmedicine.anatomical_structure030220 oncology & carcinogenesisRNA InterferenceMESH : GPI-Linked ProteinsMESH: TNF-Related Apoptosis-Inducing LigandDeath Domain Receptor Signaling Adaptor ProteinsProgrammed cell deathMESH: Cell Line Tumorc-FLIPMESH: RNA InterferenceBiologyGPI-Linked ProteinsCaspase 8Models Biological03 medical and health sciencesCell Line TumorReceptors Tumor Necrosis Factor Member 10cmedicineTRAIL-R4HumanscancerChemotherapy[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyMESH: Receptors TNF-Related Apoptosis-Inducing LigandMESH : Receptors TNF-Related Apoptosis-Inducing Ligand[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyMolecular Biology030304 developmental biologyOriginal PaperMESH: HumansMESH : Cell Line TumorMESH: ApoptosisMESH : HumansMESH: Models BiologicalMESH : CASP8 and FADD-Like Apoptosis Regulating ProteinCell BiologyMESH: Tumor Necrosis Factor Decoy ReceptorsMESH : NeoplasmsReceptors TNF-Related Apoptosis-Inducing LigandTumor Necrosis Factor Decoy ReceptorsDrug Resistance NeoplasmApoptosisMESH : RNA InterferenceMESH: GPI-Linked ProteinsMESH : ApoptosisMESH : Death Domain Receptor Signaling Adaptor ProteinsMESH: Death Domain Receptor Signaling Adaptor ProteinsTumor Necrosis Factor Decoy Receptors
researchProduct

CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death

2011

Abstract Extracellular adenosine (ADO), generated from ATP or ADP through the concerted action of the ectoenzymes CD39 and CD73, elicits autocrine and paracrine effects mediated by type 1 purinergic receptors. We have tested whether the expression of CD39 and CD73 by chronic lymphocytic leukemia (CLL) cells activates an adenosinergic axis affecting growth and survival. By immunohistochemistry, CD39 is widely expressed in CLL lymph nodes, whereas CD73 is restricted to proliferation centers. CD73 expression is highest on Ki-67+ CLL cells, adjacent to T lymphocytes, and is further localized to perivascular areas. CD39+/CD73+ CLL cells generate ADO from ADP in a time- and concentration-dependen…

AdenosineCellular differentiationChronic lymphocytic leukemia5'-Nucleotidase; Adenosine; Adenosine Diphosphate; Adenosine Triphosphate; Antigens CD; Antineoplastic Agents Phytogenic; Apyrase; Autocrine Communication; Cell Death; Cell Differentiation; Cell Movement; Cell Survival; Etoposide; Extracellular Space; GPI-Linked Proteins; Humans; Leukemia Lymphocytic Chronic B-Cell; Paracrine Communication; Receptor Adenosine A2A; Tumor Cells Cultured; Biochemistry; Immunology; Hematology; Cell BiologyMICROENVIRONMENTCD38BiochemistryACTIVATIONAdenosine TriphosphateCell MovementPhytogenichemic and lymphatic diseasesTumor Cells CulturedChronic5'-NucleotidaseEtoposideLeukemiaCulturedCell DeathTUMOR-GROWTHApyrasePurinergic receptorCell DifferentiationHematologyLymphocyticCDTumor CellsCell biologyAdenosine DiphosphateAutocrine CommunicationLeukemiaReceptorIMMUNE SUPPRESSIONReceptor Adenosine A2ACell SurvivalImmunologyAntineoplastic AgentsAdenosinergicBiologyGPI-Linked ProteinsDAMAGE-INDUCED APOPTOSISAdenosine A2AParacrine signallingAntigens CDParacrine CommunicationmedicineHumansAntigensAutocrine signallingImmunobiologyB-CellCell BiologyDAMAGE-INDUCED APOPTOSIS; T-CELLS; IMMUNE SUPPRESSION; ZAP-70 EXPRESSION; TUMOR-GROWTH; RECEPTOR; CD73; ACTIVATION; CD38; MICROENVIRONMENTmedicine.diseaseAntineoplastic Agents PhytogenicLeukemia Lymphocytic Chronic B-CellSettore MED/15 - MALATTIE DEL SANGUET-CELLSCD73Extracellular SpaceZAP-70 EXPRESSIONCD38Blood
researchProduct

CD73 Overexpression in Podocytes: A Novel Marker of Podocyte Injury in Human Kidney Disease

2021

The CD73 pathway is an important anti-inflammatory mechanism in various disease settings. Observations in mouse models suggested that CD73 might have a protective role in kidney damage

Male0301 basic medicinePathologyCCR2podocyte030232 urology & nephrologyGene ExpressionKidneyPodocyte0302 clinical medicineFocal segmental glomerulosclerosisMedicineMinimal change diseaseBiology (General)5'-NucleotidaseSpectroscopyAged 80 and overKidneymedicine.diagnostic_testPodocytesGlomerulonephritisGeneral MedicineMiddle AgedComputer Science ApplicationsChemistryProteinuriaminimal change diseasemedicine.anatomical_structureImmunohistochemistryFemaleKidney DiseasesAdultmedicine.medical_specialtyQH301-705.5Receptors CCR2GPI-Linked ProteinsImmunofluorescenceArticleCatalysisInorganic Chemistry03 medical and health sciencesHumansPhysical and Theoretical ChemistryQD1-999Molecular BiologyAgedbusiness.industryOrganic Chemistrymedicine.disease030104 developmental biologyGene Expression RegulationCD73CCR2businessBiomarkersInternational Journal of Molecular Sciences
researchProduct

Pravastatin reverses the membrane cholesterol reorganization induced by myocardial infarction within lipid rafts in CD14(+)/CD16(-) circulating monoc…

2012

International audience; Large numbers of monocytes are recruited in the infarcted myocardium. Their cell membranes contain cholesterol-rich microdomains called lipids rafts, which participate in numerous signaling cascades. In addition to its cholesterol-lowering effect, pravastatin has several pleiotropic effects and is widely used as secondary prevention treatment after myocardial infarction (MI). The aim of this study was to investigate the effects of pravastatin on the organization of cholesterol within monocyte membrane rafts from patients who had suffered myocardial infarction. Monocytes from healthy donors and acute MI patients were cultured with or without 4μM pravastatin. Lipid raf…

AdultMalemedicine.medical_specialtyStatinmedicine.drug_classCD14[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionCaveolin 1Lipopolysaccharide Receptors030204 cardiovascular system & hematologyCD16GPI-Linked ProteinsMonocytes03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCaveolaeInternal medicinemedicineHumansMolecular BiologyLipid raftCells Cultured030304 developmental biologyPravastatin0303 health sciencesCholesterolMonocyteAnticholesteremic AgentsReceptors IgGstatinCell BiologyMiddle Aged3. Good healthlipid raftEndocrinologymedicine.anatomical_structureCholesterolmyocardial infarctionchemistryGene Expression RegulationImmunologycaveolaemonocyteFemalelipids (amino acids peptides and proteins)[SDV.AEN]Life Sciences [q-bio]/Food and NutritionPravastatinmedicine.drug
researchProduct

A role for miR-142-3p in colony-stimulating factor 1-induced monocyte differentiation into macrophages

2013

AbstractThe differentiation of human peripheral blood monocytes into macrophages can be reproduced ex vivo by culturing the cells in the presence of colony-stimulating factor 1 (CSF1). Using microarray profiling to explore the role of microRNAs (miRNAs), we identified a dramatic decrease in the expression of the hematopoietic specific miR-142-3p. Up- and down-regulation of this miRNA in primary human monocytes altered CSF1-induced differentiation of monocytes, as demonstrated by changes in the expression of the cell surface markers CD16 and CD163. One of the genes whose expression is repressed by miR-142-3p encodes the transcription factor Early Growth Response 2 (Egr2). In turn, Egr2 assoc…

Macrophage colony-stimulating factorAntigens Differentiation MyelomonocyticDown-RegulationChronic myelomonocytic leukemiaReceptors Cell SurfaceCD16BiologyGPI-Linked ProteinsMonocyte–macrophage differentiationMonocytesChronic myelomonocytic leukemiaAntigens CDCell Line TumorMiR-142-3pmedicineHumansTranscription factorMolecular BiologyEarly Growth Response Protein 2Early Growth Response Protein 1Cluster of differentiationMolecular circuitryMacrophage Colony-Stimulating FactorMacrophagesReceptors IgGCell DifferentiationLeukemia Myelomonocytic ChronicCell Biologymedicine.diseaseUp-RegulationRepressor ProteinsMicroRNAsHaematopoiesisMonocyte differentiationCancer researchEgr2K562 CellsK562 cellsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research
researchProduct

Assessment of heart rate variability (HRV) in subjects with type 2 diabetes mellitus with and without diabetic foot: correlations with endothelial dy…

2021

Abstract Background Some studies have suggested that patients with diabetes and foot complications have worse cardiovascular and cerebrovascular risk profiles, higher degrees of endothelial dysfunction and arterial stiffness and a higher inflammatory background than patients with diabetes without diabetic foot complications. Patients with diabetes mellitus have an alteration in the sympathovagal balance as assessed by means of heart rate variability (HRV) analysis, which is also related to the presence of endothelial dysfunction. Other studies suggest a possible role of inflammation coexisting with the alteration in the sympathovagal balance in favor of the atherosclerotic process in a mixe…

Malemedicine.medical_specialtySympathetic Nervous SystemSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismPopulationHyperemia030209 endocrinology & metabolism030204 cardiovascular system & hematologyGPI-Linked Proteins03 medical and health sciences0302 clinical medicineHeart RateLectinsHRV diabetic foot diabetesInternal medicineDiabetes mellitusmedicineDiseases of the circulatory (Cardiovascular) systemHumansOutpatient clinicHeart rate variabilityeducationReactive hyperemiaSerpinsAgedOriginal Investigationeducation.field_of_studybusiness.industryHeartVagus NerveMiddle Agedmedicine.diseaseDiabetic footDiabetic FootCross-Sectional StudiesDiabetes Mellitus Type 2RC666-701Case-Control StudiesArterial stiffnessCardiologyCytokinesFemaleEndothelium VascularSample collectionInflammation MediatorsCardiology and Cardiovascular MedicinebusinessBiomarkersCardiovascular Diabetology
researchProduct

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma

2018

Multiple myeloma (MM) is a bone marrow plasma cell neoplasm and is the second most-common hematologic malignancy. Despite advances in therapy, MM remains largely incurable. Elotuzumab is a humanized IgG1 monoclonal antibody targeting SLAMF7, which is highly expressed on myeloma cells, and the antibody is approved for the treatment of relapsed and/or refractory (RR) MM in combination with lenalidomide and dexamethasone. Elotuzumab can stimulate robust antibody-dependent cellular cytotoxicity (ADCC) through engaging with FcγRIIIA (CD16) on NK cells and antibody-dependent cellular phagocytosis (ADCP) by macrophages. Interestingly, SLAMF7 is also expressed on cytolytic NK cells, which also expr…

0301 basic medicineReviewNK cellsLymphocyte ActivationDexamethasoneMice0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyElotuzumabLenalidomideMultiple myelomaAntibody-dependent cell-mediated cytotoxicityBortezomibSLAMF7ADCPPlasma cell neoplasmelotuzumab3. Good healthmultiple myelomaKiller Cells Naturalmedicine.anatomical_structureNK Cell Lectin-Like Receptor Subfamily K030220 oncology & carcinogenesisSLAMF7ADCCmedicine.druglcsh:Immunologic diseases. AllergyImmunologyPlasma CellsAntineoplastic AgentsmacrophageAntibodies Monoclonal HumanizedGPI-Linked Proteins03 medical and health sciencesPhagocytosisSignaling Lymphocytic Activation Molecule FamilymedicineBiomarkers TumorAnimalsHumansbusiness.industryNatural Cytotoxicity Triggering Receptor 1MacrophagesReceptors IgGNKG2Dmedicine.disease030104 developmental biologyCancer researchBone marrowbusinesslcsh:RC581-607Transcription FactorsFrontiers in Immunology
researchProduct